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Abstract
Background: HIV infection has been associated with an increased risk of fragility fracture. We explored whether or not this
increased risk persisted in HIV infected and uninfected men when controlling for traditional fragility fracture risk factors.
Methodology/Principal Findings: Cox regression models were used to assess the association of HIV infection with the risk
for incident hip, vertebral, or upper arm fracture in male Veterans enrolled in the Veterans Aging Cohort Study Virtual
Cohort (VACS-VC). We calculated adjusted hazard ratios comparing HIV status and controlling for demographics and other
established risk factors. The sample consisted of 119,318 men, 33% of whom were HIV infected (34% aged 50 years or older
at baseline, and 55% black or Hispanic). Median body mass index (BMI) was lower in HIV infected compared with uninfected
men (25 vs. 28 kg/m2; p,0.0001). Unadjusted risk for fracture was higher among HIV infected compared with uninfected
men [HR: 1.32 (95% CI: 1.20, 1.47)]. After adjusting for demographics, comorbid disease, smoking and alcohol abuse, HIV
infection remained associated with an increased fracture risk [HR: 1.24 (95% CI: 1.11, 1.39)]. However, adjusting for BMI
attenuated this association [HR: 1.10 (95% CI: 0.97, 1.25)]. The only HIV-specific factor associated with fragility fracture was
current protease inhibitor use [HR: 1.41 (95% CI: 1.16, 1.70)].
Conclusions/Significance: HIV infection is associated with fragility fracture risk. This risk is attenuated by BMI.
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Introduction
Low bone mineral density (BMD) is more common among HIV
infected than uninfected individuals, potentially placing them at
higher risk of fragility fracture.[1,2,3,4] Studies comparing fragility
fractures in HIV infected and uninfected men have been
inconclusive.[5,6,7] In a population of 1,281 HIV infected adults
on antiretroviral therapy (77% male), Collin et al. found the
incidence of first fracture to be 3.3/1,000 patient-years (95% CI
2.0, 4.6). Eighty-one percent of these fractures resulted from
trauma. Excessive alcohol consumption and hepatitis C coinfec-
tion were associated with higher fracture incidence while age,
gender, AIDS diagnosis, baseline plasma HIV RNA, body mass
index (BMI) and first protease inhibitor (PI) used were not. The
incidence rate of first fractures in this study was in the same range
as that reported in the general European population for the same
age group. Arnsten and colleagues explored associations of HIV
infection with BMD and incident fractures in HIV infected
(N= 328) and at-risk men (N=231) aged 49 years or older.[5]
They reported an association between HIV infection and a
decrease in BMD and between decreased BMD and increased
fracture incidence. However the 38% increased fracture incidence
among HIV infected men was not statistically significant, likely
due to small sample size. In a larger study of HIV infected
(N= 5,555) and uninfected men (N= 975,158), after controlling for
age and race only, Triant et al. found a higher prevalence of wrist,
hip, and vertebral fractures among HIV infected compared with
uninfected men (3.08 per 100 persons vs. 1.83; P,0.0001).[8] This
study did not include other recognized risk factors for fragility
fracture.
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The risk for fragility fracture is multifactoral, as has been
highlighted in the World Health Organization’s Fracture Risk
Assessment Tool (FRAXH). These risk factors include increasing
age, female gender, low BMI, previous fracture, parental history of
hip fracture, current smoking, glucocorticoid use, three or more
units of alcohol per day, rheumatoid arthritis, secondary
osteoporosis, and decreased femoral neck BMD. Among HIV
infected individuals, fragility fractures may be related to HIV-
specific as well as traditional risk factors. Demographic factors,
such as white race, female gender and older age increase the risk
for fractures as in the general population.[5,8] Decreased femoral
BMD has also been associated with fragility fracture risk in this
population.[5] The other FRAXH risk factors have not been
explored in the context of HIV infection. There are also fragility
fracture risk factors not included in the FRAXH but that are also
associated with HIV infection. These include: chronic hepatitis B
or C infection,[6,9] chronic obstructive pulmonary disease,[10]
coronary artery disease,[11] cerebrovascular disease,[12] and
proton pump inhibitor use.[13] The nature of these associations
likely differs by disease, thus the role that these conditions play in
the relationship between HIV infection and fragility fractures may
vary. As yet, the association between combined antiretroviral
therapy (cART) and fragility fracture remains uncertain. The
exploration of the association between cART and decreased BMD
has produced inconsistent results, with some studies demonstrating
an association,[3,14] and others not.[4,15] Exploring the contri-
bution of individual antiretrovirals, tenofovir has been associated
with an acute decrease in BMD when compared with abaca-
vir.[16,17] Protease inhibitors, particularly ritonavir, have been
associated with decreased BMD[18,19,20] when compared to
nonnucleoside reverse transcriptase inhibitor use.[18] An associ-
ation between specific antiretrovirals and fragility fractures has yet
to be determined.
Methods
Objectives
We explored whether the association between HIV infection
and hip, vertebral, and upper arm fractures in men could be
explained by traditional fragility fracture risk factors, hypothesiz-
ing that these risk factors would explain much of the association
between HIV infection and fragility fractures. Among HIV
infected men, we also analyzed the association between tenofovir
and PI use and fragility fractures. We hypothesized that neither
would be associated with an increased fracture risk.
Sample
The Veterans Aging Cohort Study Virtual Cohort (VACS-VC)
is a prospective, observational cohort of HIV infected and a 2:1
sample of age, race, gender and site matched uninfected
Veterans.[21] As described by Fultz and colleagues, the HIV
infected subjects were identified by the presence of at least two
outpatient or one inpatient International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM) codes for HIV.
Once the HIV infected subjects had been identified, each was
matched to two comparators using age (five year intervals), race/
ethnicity, geographic location, and gender. Comparators could not
have any HIV-associated diagnostic codes. The VACS-VC
represents a national sample and currently consists of 125,259
individuals (33% HIV infected) for whom demographic, pharma-
cy, and clinical data, including diagnostic codes, weight, height,
and health factors such as smoking are available. The VACS-VC
identifies all HIV infected Veterans receiving care in the Veterans
Health Administration (VHA) system. These individuals enrolled
for care in the VHA between 1997 and 2009. A small fraction of
the HIV uninfected individuals (0.15%) seroconverted after entry
into the study and were excluded from the analysis, as were those
individuals to whom they were matched, 0.39% of the total
sample.
Description of Procedures or Investigations undertaken
Definition of Outcomes. Three fracture types were included
in this study: hip, vertebral and upper arm. These were selected as
they are commonly identified as resulting from a non-traumatic
cause.[5,8,22,23] All three types were included in a composite
outcome. Unlike other authors, we excluded wrist fractures from
this analysis. Wrist fractures are the third most common type of
osteoporotic fracture. However they are far more common among
women than men.[22] Their incidence by age differs by gender: in
women, the curve is ‘‘J’’ shaped, indicating a likely association with
osteoporosis,[24] while it is bi-modal in men, one peak between 20
and 45 and another beginning at the age of 65 years.[25] The
earlier peak is thought to be more related to severe trauma than to
osteoporosis.[26] As more than 70% of our sample is younger than
60 years of age, the predominant cause of wrist fractures in this
group is likely trauma.[27]
Fracture outcomes were defined using the following ICD-9-CM
codes: hip: 820.0X, 820.1X, 820.2X, 820.3X, 820.8, 820.9;
vertebral: 805.2, 805.3, 805.4, 805.5, 805.6, 805.7; and upper
arm: 812.0X, 812.1X, 812.2X, 812.3X, 812.4X, 812.5X. The use
of these codes to identify fractures was validated by chart review of
400 randomly selected radiology reports. We compared the
presence of ICD-9-CM codes for hip, vertebral or upper arm
fractures with documentation of the fracture in radiology reports
within 2 weeks before or after the ICD-9-CM fracture date.
Overall agreement between the gold standard (documentation in
radiology reports) and ICD-9-CM codes was 97%. Agreement
beyond chance between the ICD-9-CM codes and radiologically
identified fractures (kappa) was substantial (0.77, 95% CI: 0.62–
0.90).[28]
Observation time. Observation time was calculated as the
time between cohort entry (1997–2009) and date of first fracture
for those with the event, or, for those who were censored, date of
death or the midpoint between date of last clinic visit and the
conclusion of this study (May 31, 2009), as appropriate.
Individuals whose entry into the cohort was on the same date as
their last follow-up were excluded from this analysis. As this
analysis included time varying covariates, follow-up time was
divided into six month intervals, beginning at the individual’s entry
into the cohort.
Covariates. We examined covariates identified as risk factors
for fragility fracture [29,30,31,32,33,34]: age at baseline, race/
ethnicity, BMI, past or current smoking, inhaled/oral
corticosteroid use, proton pump inhibitor (PPI) use, and
comorbid conditions.[35] Age at baseline (time of entry into the
VACS) was assessed in 10 year increments. BMI was defined as
the first available BMI from no more than six months prior to
enrollment. To address a possible nonlinear relationship between
BMI and fracture risk, both BMI and the quadratic, BMI2, were
included in the models. The comorbid conditions were also
assessed at baseline and included congestive heart failure (CHF),
pulmonary diseases, peripheral vascular disease (PVD), diabetes
mellitus (DM), alcohol abuse, drug abuse, major depressive
disorder, stroke, coronary artery disease (CAD), cerebrovascular
disease (CVD), end stage liver disease (ESLD), cirrhosis, renal
disease, chronic hepatitis B or C infection. Proton pump inhibitor
use was defined as any active prescription for a PPI from study
entry through time of fracture or censoring.
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Among HIV infected individuals, we initially controlled for
baseline CD4 count, baseline HIV-RNA levels, and use of
tenofovir, PIs, and cART.[3,36,37,38] Both tenofovir and PIs
were included as they have been shown to be associated with
decreased BMD.[39] CD4 count was categorized into 100 cell/
mm3 increments, and HIV-RNA was log10 transformed.
Corticosteroid use, tenofovir use, PI use, and cART use were
evaluated both as time-varying covariates and as cumulative
exposure to drug. To accomplish this, the data were organized as
multiple records per patient, each record being defined as a six
month interval, as described above. In each record, two variables
were created. The first noted whether or not the individual was on
the drug during the time interval (yes/no), and the second
recorded the cumulative time that the individual had been
prescribed the medication.
Ethics
The development of the VACS was approved by the
Institutional Review Boards of the VHA Connecticut Healthcare
System and Yale University School of Medicine, has been granted
a waiver of informed consent, and is HIPAA compliant.[21]
Statistical methods
Univariate statistics were used to describe the population. Chi-
square and t-test were used to compare differences by HIV status.
The percent of missing data in our study was low, ranging from
less than 1% to 11%. We used multiple imputation (MI)[40] via
the SAS Procedure MI. The imputation model included hip,
vertebral, and upper arm fractures as well as the composite
outcome, the time variables for all three fracture types, and all
covariates. Analyses of the imputed data sets were combined using
Rubin’s rule[41] as implemented in the SAS Procedure MIANA-
LYZE. For additional information on the imputation process,
please see Appendix S1.
We estimated unadjusted fracture incidence, defined as the
number of hip, vertebral or upper arm fractures per 1,000 person-
years. Using Cox regression models, we then adjusted for
covariates previously identified as risk factors for fragility fracture.
As BMI may mediate the relationship between HIV infection and
fragility fracture, we first excluded it from these analyses. We then
entered BMI into the models to evaluate whether it attenuated the
effect of HIV infection.
Initially we explored the effect of covariates on fragility fracture
risk in a combined model of HIV infected and uninfected men.
We then explored models for HIV infected and uninfected men
separately, including the same covariates as in the combined
model. In the model for HIV infected men, when both CD4
count and HIV-RNA were included in the model, neither was
significant. As they covaried (Pearson’s R: 0.30), we entered each
into the model separately. CD4 count was significantly associated
with the outcome while log HIV-RNA was not. Therefore, only
CD4 count was retained in the model. Similarly, because of
covariance, cART use could not be included in models that also
included PI and tenofovir use. As we were interested in exploring
specific drugs that might be associated with increased fracture
risk, we excluded cART use. In addition, we built one set of
models that included variables for current use of corticosteroids,
tenofovir, and PI. We then constructed different models that
replaced the variables for current use with those for cumulative
use. Cumulative use of any of these medications was not
associated with fragility fractures, thus we present only the results
from those models that included current corticosteroid, tenofovir,
and PI use.
Results
Our analysis included 119,318 men, 33% of whom were HIV
infected (Table 1), who enrolled in VACS-VC between 1997 and
2009. There were 1615 first fractures: 496 hip, 322 vertebral, and
797 upper arm fractures. There were five instances of two
fractures at the time of first fracture: four men had both vertebral
and upper arm fractures and one man had both hip and upper
arm fractures. None experienced three or more fractures at the
time of first fracture.
At enrollment, 34% of HIV infected and uninfected men were
over 50 years of age. Fifty five percent of subjects were black or
Hispanic. Because of the matched sample design, differences in
race or age were not significant. Median BMI was lower in HIV
infected than in uninfected men (25 kg/m2 versus 28 kg/m2,
p,0.0001). Mean follow-up time was shorter among HIV infected
than uninfected men (6.063.9 versus 6.963.9, p,0.0001), and the
mean age at fracture was one year older in HIV infected than
Table 1. Sample Characteristics*.
HIV infected
N= 40115
Uninfected
N= 79203 p
HIV infected and
uninfected men
Follow-up time (years) ** 6.063.9 6.963.9 ,0.0001
Age at time of fracture** 54610.0 53611 0.01
Black/Hispanic 55 55 NA{
Age .50 years at baseline 34 34 0.10
BMI (m/kg2){ 25 (22, 28) 28 (25, 32) ,0.0001
Congestive heart failure 2 2 0.75
Pulmonary diseases 6 6 0.69
Peripheral vascular disease 1.0 1.3 ,0.0001
Alcohol abuse
Drug abuse
16
19
15
12
,0.0001
,0.0001
Current smoker 61 54 ,0.0001
Major depressive disorder 7 6 ,0.0001
Coronary artery disease
Diabetes
4
7
6
12
,0.0001
,0.0001
Cerebrovascular disease/stroke 2 2 0.08
Liver disease 12 3 ,0.0001
Renal disease 4 2 ,0.0001
Corticosteroid use at baseline 5 3 ,0.0001
Any proton pump inhibitor use 41 41 0.60
HIV infected men only
Tenofovir use at baseline 3 NA --
PI use at baseline 37 NA --
On cART at any time during
follow-up
75 NA --
Duration of cART use** 2.962.5 NA --
Baseline CD4 (cells/mm3){ 274 (109, 468) NA --
Baseline HIV RNA (copies/mL){ 10722 (500, 77516) NA --
*Data are from the baseline visit and are percents unless noted otherwise.
**Mean6SD.
{ Groups matched by age and race.
{ Median (IQR).
¥ Liver disease is a composite variable composed of chronic Hepatitis B or C
infection, end stage liver disease, and/or cirrhosis.
doi:10.1371/journal.pone.0017217.t001
HIV Infection and Fragility Fractures in Men
PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e17217
uninfected men [54610 versus 53611 years, p = 0.01; median 53
(48, 61) versus 52 (46, 58)]. Peripheral vascular disease, coronary
artery disease, and diabetes were less common among HIV
infected than uninfected men (p,0.0001). In contrast, alcohol
abuse, drug abuse, current smoking, major depressive disorder,
liver disease, and renal disease were all more common among HIV
infected compared to uninfected men (p,0.0001). HIV infected
men were also more likely to have used corticosteroids at baseline
than uninfected (p,0.0001). Among HIV infected men, median
baseline CD4 count was 274 (109, 468) cells/mm3, and median
baseline HIV-RNA was 10,722 (500, 77,516) copies/mL. Thirty-
three percent had a serum HIV-RNA less than 1000 copies/ml at
enrollment, 3% used tenofovir and 37% used a PI. Over the
duration of follow-up, 75% used cART for a mean duration of
2.962.5 years.
In the combined model of HIV infected and uninfected men,
the unadjusted incidence of all fragility fractures was 2.5/1,000
person-years among HIV infected and 1.9/1,000 person-years
among uninfected men (p,0.0001). The unadjusted risk for
fragility fracture was significantly higher among HIV infected than
uninfected men [hazard ratio: 1.32 (95% CI: 1.20, 1.47)] (Table 2).
Including common risk factors for fragility fracture, with the
exception of BMI, attenuated this association, but it remained
statistically significant [1.24 (1.11, 1.39)]. When BMI and BMI2
were included in the model, the effect of HIV was further
attenuated [1.10 (0.97, 1.25)] and was no longer statistically
significant. Greater BMI was associated with a decreased risk for
fragility fracture [0.82 (0.79, 0.85)]. However, that BMI2 was also
significantly associated with fracture risk [1.002 (1.002, 1.003)]
implies that the risk for fracture is higher than expected at the
extremes of BMI.
When comparing adjusted models of fragility fracture risk in
HIV infected and uninfected men, relationships between the
covariates and fragility fracture were similar. As expected, older
age, white race, alcohol abuse, liver disease, current corticosteroid
use, smoking, and any proton pump inhibitor use increased the
risk for fragility fracture in both models. In addition, among HIV
infected men, an increase in BMI, but not BMI2, was protective
against fractures. Among uninfected men, both were significant.
Thus, among HIV infected individuals, the relationship with BMI
was linear: a higher BMI was associated with a lower risk for
fragility fracture. The relationship between BMI and fragility
fracture among HIV uninfected men is as described above.
Among HIV-specific covariates, only current PI use was
significantly associated with fragility fracture risk [1.41 (1.16,
1.70)]. Current tenofovir use [1.29 (0.99, 1.70)], and CD4 count at
baseline [1.01 (0.98, 1.05)] were not significantly associated with
fracture risk.
Discussion
Men with HIV infection were at increased risk for incident
fracture compared to uninfected, demographically similar men.
Including established risk factors, particularly baseline BMI and
BMI2, in the model attenuated the risk associated with HIV
infection. In our cohort, in addition to BMI, other important
modifiable risk factors included alcohol abuse, smoking, current
corticosteroid use, liver disease, and any proton pump inhibitor
use. As has been found in previous research, the association
between corticosteroid use and bone fracture was present while the
patient was on treatment.[42]
Among HIV infected individuals, current PI use was associated
with an increased risk of fracture. This association was evident
while the patient was on treatment. This result should be
interpreted with caution. Mean follow up time for HIV infected
male Veterans was 6.063.9 years, but mean time on cART was
Table 2. Comparative models for any fragility fracture (hip, vertebral, or humeral) in male Veterans*.
Model with HIV
only**
Model with
everything but
BMI** Full Model** Restricted to HIV+** Restricted to HIV-**
HIV 1.32 (1.20, 1.47) 1.24 (1.11, 1.39) 1.10 (0.97, 1.25) -- --
Age (10 year increments) -- 1.33 (1.26, 1.41) 1.32 (1.25, 1.40) 1.52 (1.39, 1.66) 1.32 (1.25, 1.40)
White race -- 1.74 (1.56, 1.94) 1.80 (1.60, 2.03) 1.85 (1.52, 2.25) 1.80 (1.60, 2.03)
Alcohol abuse -- 1.81 (1.53, 2.15) 1.80 (1.50, 2.17) 1.50 (1.12, 2.02) 1.80 (1.50, 2.17)
Liver disease{ -- 1.33 (1.08, 1.63) 1.38 (1.10, 1.73) 1.39 (1.03, 1.87) 1.38 (1.10, 1.73)
Current corticosteroid use -- 1.57 (1.28, 1.92) 1.45 (1.21, 1.74) 1.41 (1.06, 1.88) 1.45 (1.21, 1.74)
Smoker -- 1.44 (1.25, 1.66) 1.21 (1.04, 1.42) 1.30 (1.00, 1.67) 1.21 (1.04, 1.42)
Any proton pump inhibitor use -- 1.64 (1.47, 1.84) 1.70 (1.51, 1.92) 1.55 (1.28, 1.89) 1.70 (1.51, 1.92)
BMI -- -- 0.82 (0.79, 0.85) 0.87 (0.77, 0.99) 0.82 (0.79, 0.85)
BMI2 -- -- 1.002 (1.002, 1.003) 1.002 (1.000, 1.005) 1.003 (1.002, 1.003)
CD4/100 cells/mm3 -- -- -- 1.01 (0.98, 1.05) --
Current TDF use{ -- -- -- 1.29 (0.99, 1.70) --
Current PI use¥ -- -- -- 1.41 (1.16, 1.70) --
*Significant variables included in table. Other variables included in the model but not statistically significantly related to outcome: Pulmonary disease, peripheral
vascular disease, major depressive disorder, coronary artery disease and/or diabetes mellitus, congestive heart failure, renal insufficiency, CD4 (per 100 cells/mm3), and
tenofovir use. HIV-RNA was excluded from the model as it covaried with CD4 count (Pearson’s R: 0.30) and only CD4 count was significantly associated with fragility
fractures.
**Hazard ratio (95% confidence interval).
{ Includes end stage liver disease, cirrhosis, chronic hepatitis B or C infection.
{ TDF: tenofovir.
¥ PI: protease inhibitor.
doi:10.1371/journal.pone.0017217.t002
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only half that time (2.962.5 years) and varied widely. Thus it is
possible that PI use is a marker for disease severity and/or
duration. For example, those with the most advanced disease may
have initiated therapy with a PI earlier than those with less
advanced disease. Thus it is not clear that PI use per se is associated
with an increased risk for fracture. Neither CD4 count nor current
tenofovir use was significantly associated with fracture risk. That
tenofovir was not significantly related to fragility fracture risk may
reflect its more recent emergence on the market that PI use.
Tenofovir has only been available since 2001. Protease inhibitors,
by comparison, have been in use since the inception of VACS.
There is limited prior work addressing the relationship between
HIV infection and the risk of fragility fracture in men. Given
different outcome measures and sample populations, comparisons
among studies are difficult. Collin and colleagues explored the
incidence of all fracture types among HIV infected men and
women.[6] Triant and colleagues explored the prevalence of
wrist, hip, and vertebral fractures in HIV infected and uninfected
men and women, both separately and together.[8] Arnsten and
colleagues explored the incidence of any fracture in HIV infected
and at risk men 49 years of age and older.[5] Our study furthers
this earlier work. The difference in fracture incidence between
our study and that of Collin et al. is likely explained by their
inclusion of all fracture types in both men and women. This
difference may also explain why BMI was significant in our study
where we limited the fractures under consideration, and not in
that of Collin et al. Compared to the work of Triant and
colleagues who explored only the role of age, race, and gender,
we were able to control for a wide variety of risk factors, including
modifiable risk factors, in our analysis. Our results were similar to
those of Arnsten and colleagues. Remaining differences between
our results and those of Arnsten and colleagues may result from
the differences in outcomes: we looked at hip, vertebral and
upper arm fractures while Arnsten and colleagues looked at all
fractures. In addition, our sample size (N= 119,318) allowed us to
explore more of the risk factors for fragility fracture than was
possible in the previous study. In particular, our results support
those of Bolland and colleagues who suggest that weight, or BMI,
may mediate the relationship between HIV infection and low
BMD.[43]
There is an extensive literature suggesting an association
between decreased BMD and HIV infection.[3,44,45] However
fragility fractures occur as a result of both decreased bone strength
and injury.[46] While an important risk factor for fractures, most
individuals who experience a fragility fracture do not have a BMD
in the lowest range.[47,48,49,50] Thus, fragility fractures and low
BMD are not the same outcome.
Clinically, our work highlights the contribution of common risk
factors for fragility fracture among individuals with HIV infection.
The role of specific antiretroviral medications still requires further
exploration. In the meantime, helping patients to stop smoking
and decrease alcohol consumption is of central importance. Oral
and inhaled corticosteroids and PPIs should be used sparingly.
When treatment is unavoidable, providers should help patients
minimize other fragility fracture risk factors and should address
prevention of proximal causes of fractures, such as falls.
Strengths
Our study has several unique strengths. These include a large
and diverse national sample, incident outcomes, and data on most
of the major risk factors for fragility fracture.[51] We were able to
assess most of the FRAXH risk factors as well as others, including
comorbid disease, alcohol abuse, smoking, corticosteroid use, and
proton pump inhibitor use. Of central importance, we were also
able to control for BMI. In addition, our sample is approximately a
decade older than, but otherwise closely resembles, the HIV
infected male population of the US: the VACS-VC male
population is 44% black and 35% white while in the US HIV
infected population, 46% are black and 35% white.[27] Further,
our prior work has consistently demonstrated generalizability of
our findings to non-Veteran populations. In three major and
independent cross cohort collaborations considering associations
between timing of HIV treatment and survival, associations in
VACS data were consistent with those found in other cohorts from
Europe and North America.[52,53,54]
Limitations
Fragility fractures are far more common among women than
men. However fragility fractures among men account for 20% of
all fragility fractures and 25% of the costs.[46] One-third of all hip
fractures occur in men.[55] Post hip fracture, one-year mortality
rates are higher in men than in women (31–38% vs 12–28%,
respectively)[56], and men are almost twice as likely as women to
be institutionalized after a hip fracture.[57]
We were limited by the fact that we could only access data
subsequent to the date of VACS enrollment. This prevented our
being able to determine whether or not individuals had had a
fracture prior to enrollment. In addition, as in most cohort studies,
we had no information on parental history of hip fracture. We
have no reason to believe that parental history of hip fracture
differs by HIV status. In addition, we also used ICD-9-CM codes
to identify fractures, and despite our attempts to clearly identify
the fractures in our study as fragility fractures, we acknowledge
that some fractures may have resulted from trauma, thus our
results may overestimate fracture incidence in all subjects.
Nonetheless, our relative comparisons are robust.
Future directions
The utility of including HIV infection as a risk factor to existing
fracture risk algorithms, such as the FRAXH, requires further
investigation. As FRAXH is only valid in people over the age of 50
years, it cannot be utilized as a risk prognosticator in the majority
of HIV infected patients, thus alternatives to the FRAXH should
be explored. Finally, proximal causes of fragility fractures in the
population require further exploration. As noted earlier, a
combination of decreased BMD and injury cause fragility
fractures. While the role of decreased BMD has been explored,
that of injury, particularly falls, remains unexplored and requires
elucidation.
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